JDE-PEET’S
4.9.2020 08:02:13 CEST | Business Wire | Press release
JDE Peet's (Euronext Amsterdam: JDEP), the world’s largest pure-play coffee and tea group by revenue, today announced the appointment of Fabien Simon as Chief Executive Officer, effective 7 September 2020. He is based in Amsterdam.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200903005811/en/
Simon, who has served as a Director of JDE Peet’s since its listing, has extensive experience within the company and sector. Simon spearheaded the successful listing of JDE Peet’s on the Euronext Amsterdam stock exchange in May 2020, raising €2.58 billion in Europe’s largest IPO of the year. Between August 2014 and January 2019, he was CFO of Jacobs Douwe Egberts (JDE) and led its M&A strategy and multiple large-scale integrations.
“No one knows this business better than Fabien,” said Olivier Goudet, Chairman of JDE Peet’s and CEO & Managing Partner of JAB. “Not only did Fabien lead the successful IPO of JDE Peet’s, he oversaw the very creation of JDE and its transformation into a global coffee & tea powerhouse.”
Simon’s appointment follows the strong performance of JDE Peet’s in the first half of 2020, during which time the company demonstrated the resilience of its business and brands despite the unprecedented economic and social disruption of COVID-19.
“JDE Peet’s is a rare business with a proven track record of performance across economic, market and consumer cycles,” added Simon. “It is a privilege to lead this company into its next phase of growth, building on our unique portfolio of brands, products and channels to meet the needs of our customers and capitalize on the myriad opportunities to gain market share in coffee and tea globally. I look forward to leading this incredible business for years to come.”
Simon succeeds Casey Keller who decided to return to the United States to be with his family who were unable to relocate to Amsterdam due to health and safety implications related to the pandemic.
Goudet added, “On behalf of the Board, I would like to thank Casey for his contributions to this organization. Casey joined Peet’s Coffee as CEO in 2018 and, under his leadership, achieved strong growth and record market share gains. He then took the helm of JDE Peet’s and demonstrated remarkable leadership and great results amidst an extraordinary operating environment. We wish him and his family the very best.”
Simon is appointed as CEO by the Board. The appointment will be tabled for formalization at the next general meeting.
NOTE TO EDITORS – EXECUTIVE BIOGRAPHY & PHOTOGRAPHY
Fabien Simon, a French national who has lived in Amsterdam since 2014, has been a Director of JDE Peet’s since its inception and was responsible for leading its successful listing on the Euronext Amsterdam stock exchange in May 2020. He has also served as Partner and CFO of JAB since January 2019 and as chairman of its pet care platform. Simon will step down from all of his other JAB roles, including his board positions at Keurig Dr Pepper and Krispy Kreme and his JAB CFO role. Between August 2014 and January 2019, Simon was CFO of JDE, during which time he led its M&A strategy and multiple large-scale integrations. Prior to JDE, he spent 13 years at Mars, holding various finance leadership roles, including Asia Pacific CFO, Vice President and CFO Petcare Europe and Finance Director Europe. Simon also spent eight years at Valeo in a variety of leadership roles, including Finance Director. He holds a Master's degree in Finance and Economics from the University of Picardie Jules Verne, Amiens and a Chartered Accountant Certificate. He lives in Amsterdam with his wife and three children.
About JDE Peet’s
JDE Peet’s is the world's largest pure-play coffee and tea group by revenue, serving approximately 130 billion cups of coffee and tea in the financial year ended 31 December 2019 (“FY”) in more than 100 developed and emerging countries. With a portfolio of more than 50 leading global, regional and local coffee and tea brands, JDE Peet’s offers an extensive range of high-quality and innovative coffee and tea products and solutions to serve consumer needs across markets, consumer preferences and price levels. In FY 2019, JDE Peet’s generated total sales of EUR 6.9 billion and had on average 21,255 employees worldwide. The JDE Peet’s global portfolio includes Jacobs, Peet’s, L’OR, Senseo, Tassimo and Ti Ora.
For more information please visit www.JDEPeets.com .
This press release contains information which is to be made publicly available under Regulation (EU) 596/2014.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200903005811/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
